Drug News

Dollar Landscape of Biological Drug API Manufacturing Services – A Decade of Growth and Collaboration (2023-2033)

The Biological Drug API Manufacturing Services Market Report for 2023-2033, presented by Research and Markets, underscores key developments in the sector. It anticipates robust revenue growth, exceeding US$8 billion in 2023, and highlights various trends, opportunities, and challenges.

The report emphasizes the critical role of Active Pharmaceutical Ingredients (APIs) in medical treatments, addressing conditions such as cancer, cardiovascular disease, diabetes, infectious diseases, pain relief, and respiratory conditions. APIs contribute significantly to advancing therapeutic solutions by developing medications targeting bacterial and viral infections.

Strategic partnerships and collaborations within the pharmaceutical industry are identified as significant growth drivers for Contract Manufacturing Organizations (CMOs) involved in biological drug API production. These collaborations, involving pharmaceutical companies, universities, and research centers, facilitate resource sharing, knowledge exchange, and innovation. Consortia or alliances with multiple pharmaceutical companies are highlighted for their potential to broaden clientele, reduce reliance on a single partner, and foster collaborative research and development.

The report delves into various market dynamics, citing factors that drive growth, including biological patent expirations, outsourcing, growing investments in orphan drugs, and the increasing importance of single-use technology over the next decade. It also outlines restraining factors such as challenges in manufacturing APIs for biologics, pricing pressure, regulatory scenarios, and concerns related to excessive production. The report identifies opportunities in advancements in bioprocessing techniques, customization, flexibility in manufacturing, and the potential for growth in emerging economies.

Market segmentation is provided based on manufacturing type (outsourced and in-house), application (vaccines, mABs, insulin analogues, interferon therapies, human growth hormones, and others), and expression platform (mammalian cell cultures, microbial fermentations, and others).

Leading companies in the Biological Drug API Manufacturing Services Market, including AbbVie Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Cytovance Biologics, FUJIFILM Diosynth Biotechnologies, Lonza, Piramal Pharma Solutions, Samsung Biologics, and Thermo Fisher Scientific Inc., are profiled in the report.

The report also includes revenue forecasts for five regional and 22 national markets, providing insights into market prospects in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In addition to quantitative forecasts, the report offers qualitative analyses, including market dynamics, drivers, opportunities, and restraints.

In summary, the report, spanning over 260 pages, serves as a comprehensive resource for industry stakeholders, offering valuable insights into current market trends and future growth prospects within the Biological Drug API Manufacturing Services sector.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker